<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513381</url>
  </required_header>
  <id_info>
    <org_study_id>14/YH/1125</org_study_id>
    <nct_id>NCT02513381</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome</brief_title>
  <official_title>The Effect of Colecalciferol (Vitamin D) on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Double Blind Randomised Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull University Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Hull</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hull University Teaching Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind randomised placebo-controlled study involving women with polycystic&#xD;
      ovary syndrome (PCOS). The patients will be randomised either to Vitamin D 3200 IU or placebo&#xD;
      for three months. The main hypothesis of this study is &quot;Vitamin D improves hormonal,&#xD;
      metabolic and cardiovascular risk markers in women with PCOS&quot;.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a very common condition in women which could present with&#xD;
      irregular periods, excessive hair growth on body, acne and cysts in the ovaries. PCOS is also&#xD;
      associated with increased risk of problems later in life like diabetes, high cholesterol&#xD;
      levels and heart disease. One of the risk factors for having increased incidence of such&#xD;
      problems in PCOS patients could be low vitamin D levels as many women with polycystic ovary&#xD;
      syndrome (PCOS) are vitamin D deficient. Vitamin D supplementation may have a beneficial&#xD;
      effect on insulin levels and fat around the abdomen. It has been seen in previous research&#xD;
      studies that low level of vitamin D is related to a greater risk of diabetes and heart&#xD;
      disease. Low vitamin D levels are also associated with fat in the liver. The amount of fat in&#xD;
      the liver is a sign of early liver disease. So, in this study the investigators want to&#xD;
      supplement women having PCOS and vitamin D deficiency with vitamin D (3,200 IU) and examine&#xD;
      the effects on hormones related to PCOS and risk factors for diabetes and heart disease in&#xD;
      them.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular risk assessment by hs-CRP, HOMA (fasting glucose &amp; insulin) and fasting lipid profile</measure>
    <time_frame>Three months supplementation with Vitamin D3 3200IU or placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormonal parameters including testosterone, SHBG and FAI.</measure>
    <time_frame>Three months supplementation with Vitamin D3 3200IU or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker hs-CRP</measure>
    <time_frame>Three months supplementation with Vitamin D3 3200IU or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function by EndoPAT</measure>
    <time_frame>Three months supplementation with Vitamin D3 3200IU or placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Vitamin D3, 3200IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitamin D3, 3200IU</intervention_name>
    <description>Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.</description>
    <arm_group_label>Vitamin D3, 3200IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Caucasian women, aged 18-45 years, with confirmed diagnosis of PCOS based on all three&#xD;
             diagnostic criteria of the Rotterdam consensus [21].&#xD;
&#xD;
          2. Irregular periods with raised FAI&#xD;
&#xD;
          3. Vitamin D &lt; 50 nmol/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, Cushing's disease and&#xD;
             androgen-secreting tumours will be excluded by appropriate tests if clinically&#xD;
             indicated.&#xD;
&#xD;
          2. Any concurrent illness including type 2 diabetes, subjects who are on any medication&#xD;
             (including medications that interfere with calceotrophic hormones) for the preceding 6&#xD;
             months.&#xD;
&#xD;
          3. Women planning to conceive.&#xD;
&#xD;
          4. Women who are using any oral or implantable contraceptives or any other treatments&#xD;
             likely to affect ovarian function, insulin sensitivity or lipids for at least 3 months&#xD;
             before entering the study. Stable dose of metformin for 3 months is allowed. Subjects&#xD;
             will be advised to use barrier contraception during the study period.&#xD;
&#xD;
          5. eGFR&lt;60.&#xD;
&#xD;
          6. Hypersensitivity to vitamin D or any of the excipients in the product.&#xD;
&#xD;
          7. Peanut or soya allergy.&#xD;
&#xD;
          8. Nephrolithiasis.&#xD;
&#xD;
          9. Diseases or conditions resulting in hypercalcaemia and/or hypercalciuria.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thozhukat Sathyapalan, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hull</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael White Centre for Diabetes and Endocrinology</name>
      <address>
        <city>Hull</city>
        <state>East Yorkshire</state>
        <zip>HU3 2RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.mdpi.com/2072-6643/11/1/188/htm</url>
    <description>Publication Link</description>
  </link>
  <results_reference>
    <citation>Javed Z, Papageorgiou M, Deshmukh H, Kilpatrick ES, Mann V, Corless L, Abouda G, Rigby AS, Atkin SL, Sathyapalan T. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. Nutrients. 2019 Jan 17;11(1). pii: E188. doi: 10.3390/nu11010188.</citation>
    <PMID>30658483</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

